Prostate Cancer Market Overview
The Prostate Cancer Market in the seven major markets (7MM) was valued at nearly USD 12 billion in 2023 and is projected to grow steadily through 2034. The United States holds the largest market share, driven by a high prevalence of the disease and advanced healthcare infrastructure. According to DelveInsight, there were approximately 3.6 million prevalent cases of prostate cancer in the U.S. in 2023. Among the EU4 and the UK, Germany reported the highest number of metastatic castration-resistant prostate cancer (mCRPC) cases, while Spain had the lowest.
Prostate cancer is predominantly diagnosed in men aged 65 to 74, with the median age of diagnosis being 66. The disease typically grows slowly, but advanced stages such as mCRPC require aggressive treatment to improve outcomes.
Download the report to understand which factors are driving Prostate Cancer epidemiology trends @ Prostate cancer patient pool
Prostate Cancer Epidemiology
DelveInsight’s analysis provides a detailed segmentation of prostate cancer epidemiology across the 7MM for the period 2020–2034. The report breaks down the data into:
Total Prevalent Cases of Prostate Cancer.
Five-year Prevalent Cases of Prostate Cancer.
Age-specific Cases of Prostate Cancer.
Cases segmented by clinical stages, including nmCSPC (non-metastatic castrate-sensitive prostate cancer), mCSPC (metastatic castrate-sensitive prostate cancer), nmCRPC (non-metastatic castration-resistant prostate cancer), and mCRPC.
These insights are invaluable for understanding the current patient population and predicting future trends, which can guide healthcare strategies and therapeutic developments
For a deeper understanding of Prostate Cancer Epidemiology, clinical trials, and market dynamics, visit DelveInsight’s Prostate Cancer Market Insights.
Current Prostate Cancer Therapies
Prostate cancer treatment varies depending on the stage and severity of the disease. For localized cancer confined to the prostate, options include surgery, radiation, and sometimes hormone therapy. Advanced stages often require a combination of therapies, including androgen deprivation therapy (ADT), chemotherapy, radiopharmaceuticals, and immunotherapy.
Several approved therapies dominate the Prostate Cancer Market. These include:
AKEEGA (Janssen Pharmaceutical)
JEVTANA (Sanofi)
LYNPARZA (AstraZeneca)
TALZENNA (Pfizer)
XOFIGO (Bayer)
XTANDI (Astellas Pharma/Pfizer)
ZYTIGA (Janssen Pharmaceutical)
RUBRACA (Clovis Oncology)
ERLEADA (Janssen Pharmaceutical)
NUBEQA (Bayer)
A standout addition to the treatment arsenal is Novartis’ PLUVICTO, a radioligand therapy approved in 2022. PLUVICTO has shown strong commercial uptake, particularly in the mCRPC segment, due to its ability to significantly improve survival outcomes for patients with limited treatment options.
Discover which therapies are expected to grab the Prostate Cancer market share @ Prostate Cancer Market Report
Emerging Prostate Cancer Drugs
The pipeline for Prostate Cancer drugs is robust, featuring several promising therapies in various stages of clinical development. Key players and their innovative therapies include:
CAN-2409 (Candel Therapeutics): A gene therapy targeting localized prostate cancer.
KPG-121 (Kangpu Biopharmaceuticals).
Capivasertib (AstraZeneca): A next-generation AKT inhibitor.
ARV-110 (Arvinas): A targeted protein degrader.
D-7300 (Daiichi Sankyo).
EPI-7386 (Essa Pharma): An investigational androgen receptor (AR) inhibitor.
177Lu-PNT2002 (Eli Lilly/POINT Biopharma): A radioligand therapy.
TLX591 (Telix Pharmaceuticals): A novel radiopharmaceutical.
Cabozantinib (Exelixis).
ModraDoc006/r (Modra Pharmaceuticals).
Vudalimab (Xencor).
TAS-116 (Taiho Pharmaceutical).
ZEN-3694 (Zenith Epigenetics).
Vobramitamab Duocarmazine (MacroGenics).
The competitive landscape reflects a strong focus on addressing unmet needs, particularly in advanced stages of the disease, such as mCRPC. As these therapies advance through clinical trials and receive regulatory approvals, they are expected to transform the Prostate Cancer Market.
For more detailed insights into therapies, trials, and market dynamics, download the full Prostate Cancer Market report
Recent Developments in Prostate Cancer Research
Several significant developments have occurred recently in the field of prostate cancer:
ESSA Pharma terminated its Phase II clinical trial for masofaniten (formerly EPI-7386), an androgen receptor inhibitor, after an interim review.
Clarity Pharmaceuticals launched a Phase III trial for its 64Cu-SAR-bisPSMA diagnostic targeting biochemical recurrence (BCR) in prostate cancer.
Bayer’s NUBEQA is being explored in combination with LHRHa and EBRT for non-metastatic CSPC with high-risk BCR.
These advancements highlight the dynamic nature of the Prostate Cancer Clinical trial landscape and the continuous efforts to improve patient outcomes.
Market Dynamics and Drivers
The Prostate Cancer Market is undergoing rapid growth, driven by:
Advancements in Targeted Therapies: The emergence of PARP inhibitors (e.g., olaparib, niraparib, rucaparib, talazoparib) and radioligand therapies like PLUVICTO is revolutionizing treatment paradigms.
Improved Diagnostic Techniques: Enhanced imaging and biomarker testing are enabling earlier detection and more precise treatment strategies.
Unmet Medical Needs: The heterogeneity of prostate cancer and treatment resistance in mCRPC patients are driving innovation in therapeutic approaches.
Despite these drivers, several challenges persist, including high treatment costs, under-reporting of cases, and delays in treatment initiation. Addressing these barriers is essential for maximizing the impact of new therapies.
Learn more about the market of Prostate Cancer @ Prostate Cancer Treatment Market
Conclusion
The Prostate Cancer Market is on the brink of transformative growth, fueled by innovative therapies, expanding patient populations, and improved diagnostic capabilities. Established therapies like XTANDI and emerging treatments like CAN-2409 and PLUVICTO are setting new benchmarks for efficacy and survival outcomes. Companies such as Janssen Pharmaceutical, AstraZeneca, Bayer, and Novartis are leading the charge, ensuring that patients have access to cutting-edge Prostate Cancer drugs and therapies.
As research progresses, the integration of novel approaches and targeted treatments will continue to reshape the Prostate Cancer treatment landscape, offering hope to millions of patients worldwide. DelveInsight’s comprehensive market analysis provides invaluable insights for stakeholders aiming to navigate this dynamic and evolving field effectively.
Discover which therapies are poised to dominate the prostate cancer market and learn more about clinical trials, FDA approvals, and treatment advancements by accessing the full Prostate Cancer Market report.
About DelveInsight
DelveInsight is a leading business consultancy and market research firm specialized in life sciences. It assists pharmaceutical companies by offering comprehensive, end-to-end solutions to improve their performance. Access all the healthcare and pharmaceutical market Competitive Intelligence Solutions.
Related Reports:
Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market Outlook
Metastatic Prostate Cancer Market | Companies, Emerging Therapies
Hormone Sensitive Advanced Prostate Cancer Market Forecast
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Outlook
Non-metastatic Prostate Cancer (nmPC) Treatment Market Size 2034
